Site-Directed Integration for Consistent CHO Cell Line Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell line development methods for producing therapeutic proteins, particularly using CHO cells, are resource-intensive and time-consuming due to random gene integration, leading to genetic and phenotypic variability among clones, which complicates early developability assessment and increases the risk of late drug candidate failures.
Innovation Solution
A novel method combining site-directed integration (SDI) with expression construct components and a pre-CLD host cell line selection workflow to generate a production-competent cell bank, allowing for targeted integration of genes of interest into transcriptionally active genomic regions, reducing the need for extensive screening and generating cells with consistent transcription rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If random integration of genes of interest is used, then high protein titers can be achieved in a relatively short time period, but genetic and phenotypic variability among clones increases and extensive screening is required
Solution Approach 1:
The patent applies local quality by targeting specific genomic locations (integration sites) that are pre-characterized to support high and stable transcription. Instead of random integration, the method selects specific loci with favorable epigenetic regulation, ensuring consistent protein production across clones while maintaining high titers.
Solution Approach 2:
The patent implements preliminary action by pre-identifying and pre-characterizing genomic locations before introducing the gene of interest. These pre-selected sites are known to support high transcription and stable expression, eliminating the need for extensive post-integration screening and ensuring consistent results from the outset.
2Quantity of substance
If random integration is used, then multiple copies of the gene can be integrated (5-20 copies), but transcription level is impacted by epigenetic regulation at different genomic locations
Solution Approach 1:
The patent applies local quality by selecting specific genomic locations known to have favorable epigenetic regulation and high transcriptional activity. This ensures that regardless of the number of copies integrated, each copy expresses at a consistent and high level, eliminating the variability caused by random integration sites.
3Productivity
If high levels of foreign protein expression are introduced, then evolved pressure towards increased folding and secretory capacity is created, but cell line development becomes more complex and time-consuming
Solution Approach 1:
The patent implements preliminary action by pre-selecting genomic locations that are already equipped to support high transcription and protein production. This preliminary selection of optimal integration sites reduces the subsequent need for complex screening and adaptation processes, maintaining high expression levels while simplifying the overall development process.
Data Source
AI summary
The present invention relates to an improved method for cell line development (CLD) which is generally applicable to production of any therapeutic protein that can be produced using mammalian Cell lines and in particular Chinese Hamster Ovary (CHO) cells.The method combines site-directed integration (SDI), expression construct components improving the post-transcriptional processing of the gene of interest (GOI) and the introduction of a onetime pre-CLD host cell line selection workflow to generate a production competent cell line that can then be used in multiple CLD efforts using SDI from that point on.